Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

AN2 Therapeutics, Inc. Common Stock (ANTX)

Pharmaceutical Preparations

https://www.an2therapeutics.com

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

1800 EL CAMINO REAL, SUITE D
MENLO PARK, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/25/2022

Market Cap

29,839,446

Shares Outstanding

29,740,000

Weighted SO

29,741,445

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

Beta

-0.1130

Last Div

0.0000

Range

0.87-22.22

Chg

-0.0201

Avg Vol

458017

Mkt Cap

29839446

Exch

NASDAQ

Country

Phone

650-331-9090

DCF Diff

0.3241

DCF

0.6630

Div Yield

0.0000

P/S

372.9931

EV Multiple

-0.0431

P/FV

0.3032

Div Yield %

0.0000

P/E

-0.4612

PEG

0.0165

Payout

0.0000

Current Ratio

10.6091

Quick Ratio

10.6091

Cash Ratio

2.6433

DSO

1368.7500

DIO

0.0000

Op Cycle

1368.7500

DPO

17200.6250

CCC

-15831.8750

Gross Margin

0.5000

Op Margin

-889.6375

Pretax Margin

-808.2125

Net Margin

-808.2125

Eff Tax Rate

0.2835

ROA

-0.5960

ROE

-0.5472

ROCE

-0.7236

NI/EBT

1.0000

EBT/EBIT

0.9085

EBIT/Rev

-889.6375

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

-99.4008

CF/Debt

0.0000

Equity Multi

1.1030

Rec Turnover

0.2667

Pay Turnover

0.0212

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0007

OCF/Share

-2.0401

FCF/Share

-2.0401

Cash/Share

3.5051

OCF/Sales

-760.5625

FCF/OCF

1.0000

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

0.3032

P/B

0.3032

P/S

372.9931

P/E

-0.4612

P/FCF

-0.4904

P/OCF

-0.4901

P/CF

-0.4901

PEG

0.0165

P/S

372.9931

EV Multiple

-0.0431

P/FV

0.3032

DPS

0.0000

Latest Headlines (EST)

No Headlines Found

Revenue Product Segmentation

Dividend History

Cash Value	Ex-Dividend Date	Declaration Date	Record Date	Pay Date
0.66	01/11/2018	11/30/-0001	11/30/-0001	11/30/-0001
0.66	10/12/2017	11/30/-0001	11/30/-0001	11/30/-0001
0.66	07/12/2017	11/30/-0001	11/30/-0001	11/30/-0001
0.66	04/11/2017	11/30/-0001	11/30/-0001	11/30/-0001
0.66	01/11/2017	11/30/-0001	11/30/-0001	11/30/-0001
0.66	10/12/2016	11/30/-0001	11/30/-0001	11/30/-0001
0.66	07/13/2016	11/30/-0001	11/30/-0001	11/30/-0001
0.66	04/13/2016	11/30/-0001	11/30/-0001	11/30/-0001
0.66	01/13/2016	11/30/-0001	11/30/-0001	11/30/-0001
0.66	10/13/2015	11/30/-0001	11/30/-0001	11/30/-0001
0.58	07/13/2015	11/30/-0001	11/30/-0001	11/30/-0001

Year	Purchases	Sales	Total Bought	Total Sold

Transaction Date	Name	Type Of Owner	Price	Securities Owned	Securities Transacted	Security Name	Transaction Type

Less Than 3 Months

516.02K Shares Bought (100.00 %)

0.00 Shares Sold (0.00%)

3 - 6 Months

769.42K Shares Bought (70.63 %)

319.93K Shares Sold (29.37%)

6 - 9 Months

2.58K Shares Bought (18.26 %)

11.56K Shares Sold (81.74%)

9 - 12 Months

1.78M Shares Bought (87.93 %)

244.14K Shares Sold (12.07 %)

Investor Name	Investment Discretion	Type of Security	Shares Owned	Avg Price Paid	Market Value	Change In Market Value	Change In Market Value (%)	Ownership	Weight

Date	Investors Holding	Closed Positions	Increased Positions	Reduced Positions	New Positions	Total Invested	Put/Call Ratio	Total Calls	Total Puts

Owner	Shares Owned

	2021	2023	2024	2024	1970
Revenue	0.00	0.00	▲ 80.00K	▼ 0.00
Cost Of Revenue	0.00	▲ 20.00K	▲ 40.00K	▼ 0.00
Gross Profit	0.00	▼ -20.00K	▲ 40.00K	▼ 0.00
Gross Profit Ratio	0.00	0.00	▲ 0.50	▼ 0.00	▼
Research And Development Expenses	5.81M	▲ 8.75M	▲ 14.92M	▼ 14.66M	▼
General And Administrative Expenses	1.78M	▲ 3.72M	▲ 3.90M	▼ 3.64M	▼
Selling And Marketing Expenses	0.00	0.00	0.00	0.00
Selling General And Administrative Expenses	1.78M	▲ 3.72M	▲ 3.90M	▼ 3.64M	▼
Other Expenses	22.00K	▼ 4.00K	▲ 1.92M	▼ 1.68M	▼
Operating Expenses	7.59M	▲ 12.48M	▲ 18.82M	▼ 18.30M	▼
Cost And Expenses	7.59M	▲ 12.48M	▲ 18.82M	▼ 18.30M	▼
Interest Income	27.00K	▲ 630.00K	▼ 0.00	0.00
Interest Expense	0.00	▲ 945.00K	▼ 716.00K	▼ 0.00
Depreciation And Amortization	0.00	▼ -927.00K	▲ 18.82K	▲ 18.30M	▼
Ebitda	-7.59M	▼ -12.48M	▼ -18.82M	▲ -18.30M	▼
Ebitda Ratio	0.00	0.00	▼ -100.00	▲ 0.00	▼
Operating Income	-7.59M	▼ -12.48M	▼ -18.82M	▲ -18.30M	▼
Operating Income Ratio	0.00	0.00	▼ -235.19	▲ 0.00	▼
Total Other Income Expenses Net	22.00K	▲ 634.00K	▲ 1.92M	▼ 1.68M	▼
Income Before Tax	-7.55M	▼ -11.84M	▼ -16.90M	▲ -16.62M	▼
Income Before Tax Ratio	0.00	0.00	▼ -100.00	▲ 0.00	▼
Income Tax Expense	0.00	▲ 945.00K	▼ -18.82K	▼ -18.30M	▼
Net Income	-7.55M	▼ -12.79M	▼ -16.90M	▲ -16.62M	▼
Net Income Ratio	0.00	0.00	▼ -100.00	▲ 0.00	▼
Eps	-0.42	▼ -0.66	▲ -0.57	▲ -0.56	▼
Eps Diluted	-0.42	▼ -0.66	▲ -0.57	▲ -0.56	▼
Weighted Average Shs Out	18.14M	▲ 19.40M	▲ 29.74M	▲ 29.76M	▼
Weighted Average Shs Out Dil	18.14M	▲ 19.40M	▲ 29.74M	▲ 29.76M	▼